Histology and molecular pathology of pediatric brain tumors

Journal of Child Neurology

Volumn 24, Issue 11, 2009, Pages 1375-1386

  Pfister, Stefan ^a,b,d   Hartmann, Christian ^b,c   Korshunov, Andrey ^b,c  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d INF 580   (Germany)

Author keywords

Ependymoma; Medulloblastoma; Molecular genetics; Pilocytic astrocytoma; Translational oncology

Indexed keywords

APC PROTEIN; ATM PROTEIN; B RAF KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; Y BOX BINDING PROTEIN 1;

ASTROCYTOMA; BRAIN TUMOR; CANCER GRADING; CANCER INCIDENCE; CHILDHOOD CANCER; CHOROID PLEXUS TUMOR; CONFERENCE PAPER; CRANIOPHARYNGIOMA; DIAGNOSTIC ACCURACY; DIFFUSE ASTROCYTOMA; EPENDYMOMA; GENE LOCUS; GENE OVEREXPRESSION; GERM CELL TUMOR; GLIOMA; HUMAN; LYMPHOMA; MEDULLOBLASTOMA; MENINGIOMA; MOLECULAR GENETICS; NEUROPATHOLOGY; PILOCYTIC ASTROCYTOMA; PILOMYXOID ASTROCYTOMA; PINEAL BODY TUMOR; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ASTROCYTOMA; BRAIN NEOPLASMS; CHILD; EPENDYMOMA; HUMANS; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RHABDOID TUMOR; TERATOMA;

EID: 70449134364     PISSN: 08830738     EISSN: 17088283     Source Type: Journal    
DOI: 10.1177/0883073809339213     Document Type: Conference Paper

References (53)

1. Pollack L., Stewart S., Thompson T., Li J. Stat bite: Childhood cancer deaths by site, 2004. J Natl Cancer Inst. 2008;100(3):165.
2. Kaatsch P., Rickert C., Kühl J., Schüz J., Michaelis J. Population-based epidemiologic data on brain tumors in German children. Cancer. 2001;92(12):3155-3164.
3. Louis D., Ohgaki H., Wiestler O., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;114(2):97-109.
4. Burkhard C., Di Patre P., Schüler D., et al. A population-based study of the incidence and survival rates in patients with pilocytic astrocytoma. J Neurosurg. 2003;98(6):1170-1174.
5. Broniscer A., Baker SJ, West AN, et al. Clinical and molecular characteristics of malignant transformation of low-grade glioma in children. J Clin Oncol. 2007;25(6):682-689.
6. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479-489.
7. Watanabe K., Sato K., Biernat W., et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin Cancer Res. 1997;3(4):523-530.
8. Pfister S., Janzarik W., Remke M., et al. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008;118(5):1739-1749.
9. Sharma M., Zehnbauer B., Watson M., Gutmann DH Ras pathway activation and an oncogenic Ras mutation in sporadic pilocytic astrocytoma. Neurology. 2005;65(18):1335-1336.
10. Janzarik W., Kratz C., Loges N., et al. Further evidence for a somatic KRAS Mutation in a low-grade Astrocytoma. Neuropediatrics. 2007;38(2):1-3.
11. Bar E., Lin A., Tihan T., Burger PC, Eberhart CG Frequent gains at chromosome 7q34 involving BRAF in pilocytic astrocytoma. J Neuropathol Exp Neurol. 2008;67(9):878-887.
12. Deshmukh H., Yeh TH, Yu J., et al. High-resolution, dual-platform aCGH analysis reveals frequent HIPK2 amplification and increased expression in pilocytic astrocytomas. Oncogene. 2008;27(34):4745-4751.
13. Jones DTW, Kocialkowski S., Liu L., et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 2008;68(21):8673-8677.
14. Sievert A., Jackson E., Gai X., et al. Duplication of 7q34 in pediatric low-grade astrocytomas detected by high-density single-nucleotide polymorphism-based genotype arrays results in a novel BRAF fusion gene. Brain Pathol [Epub ahead of print, 2008].
15. Rickert CH, Strater R., Kaatsch P., et al. Pediatric High-Grade Astrocytomas Show Chromosomal Imbalances Distinct from Adult Cases. Am J Pathol. 2001;158(4):1525-1532.
16. Raffel C., Frederick L., O'Fallon JR, et al. Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res. 1999;5(12):4085-4090.
17. Bredel M., Pollack IF, Hamilton RL, James CD Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res. 1999;5(7):1786-1792.
18. Sung T., Miller D., Hayes R., Alonso M., Yee H., Newcomb EW Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas. Brain Pathol. 2000;10(2):249-259.
19. Cheng Y, Ng H, Zhang S, et al. Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol. 1999;30(11):1284-1290. 20. Korshunov A, Sycheva R, Gorelyshev S, Golanov A. Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. Mod Pathol. 2005;18(9): 1258-1263.
20. Faury D., Nantel A., Dunn SE, et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol. 2007;25(10):1196-1208.
21. Pollack IF, Finkelstein SD, Woods J., et al. Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med. 2002;346(6):420-427.
22. Hargrave D., Bartels U., Bouffet E. Diffuse brainstem glioma in children: Critical review of clinical trials. Lancet Oncol. 2006;7(3):241-248.
23. Recinos P., Sciubba D., Jallo G. Brainstem tumors: Where are we today? Pediatr Neurosurg. 2007;43(3):192-201.
24. Finlay J., Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: A historical-and futuristic-perspective. J Neurooncol. 2005;75(3):253-266.
25. Godfraind C. Classification and controversies in pathology of ependymomas. Childs Nerv Syst. 2009 [Epub ahead of print]. 27. Dyer S, Prebble E, Davison V, et al. Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. 2002;161(6):2133-2141.
26. Mendrzyk F., Korshunov A., Benner A., et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12(7pt 1):2070-2079.
27. Modena P., Lualdi E., Facchinetti F., et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24(33):5223-5233.
28. Milde T., Pfister S., Korshunov A., et al. Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. Genes Chromosomes Cancer. 2009;48(3):229-238.
29. Rand V., Prebble E., Ridley L., et al. Investigation of chromosome 1q reveals differential expression of members of the S100 family in clinical subgroups of intracranial paediatric ependymoma. Br J Cancer. 2008;99(7):1136-1143.
30. Monoranu CM, Huang B., Zangen IL, et al. Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomas. Cancer Genet Cytogenet. 2008;182(1):18-26.
31. Taylor MD, Poppleton H., Fuller C., et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8(4):323-335.
32. Tabori U., Ma J., Carter M., et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. 2006;24(10):1522-1528.
33. Ridley L., Rahman R., Brundler M-A., et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol. 2008;10(5):675-689.
34. Tabori U., Wong V., Ma J., et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer. 2008;99(7):1129-1135.
35. Wolff JEA, Sajedi M., Brant R., Coppes MJ, Egeler RM Choroid plexus tumours. Br J Cancer. 2002;87(10):1086-1091.
36. Krutilkova V., Trkova M., Fleitz J., et al. Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. Eur J Cancer. 2005;41(11):1597-1603.
37. Mendrzyk F., Radlwimmer B., Joos S., et al. Genomic and protein expression profiling identifies CDK6 as novel independent prognostic marker in medulloblastoma. J Clin Oncol. 2005;23(34):8853-8862.
38. McCabe Mgmbb, Ichimura KP, Liu LP, et al. High-Resolution Array-Based Comparative Genomic Hybridization of Medulloblastomas and Supratentorial Primitive Neuroectodermal Tumors. J Neuropathology Experimental Neurology. 2006;65(6):549-561.
39. Rossi M., Conroy J., McQuaid D., Nowak NJ, Rutka JT, Cowell JK. Array CGH analysis of pediatric medulloblastomas. Genes Chromosomes Cancer. 2006;45(3):290-303.
40. Adesina A., Nguyen Y., Mehta V., et al. FOXG1 dysregulation is a frequent event in medulloblastoma. J Neurooncol. 2007;85(2):111-122.
41. de Bont JM, Packer RJ, Michiels EM, den Boer ML, Pieters R. Biological background of pediatric medulloblastoma and ependymoma: A review from a translational research perspective. Neuro Oncol. 2008;10(6):1040-1060.
42. Ellison DW, Onilude OE, Lindsey JC, et al. ß-Catenin status predicts a favorable outcome in childhood medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour Committee. J Clin Oncol. 2005;23(31):7951-7957.
43. Clifford S., Lusher M., Lindsey J., et al. Wnt/Wingless pathway activation and chromosome 6 loss characterise a distinct molecular sub-group of medulloblastomas associated with a favourable prognosis. Cell Cycle. 2006;5(22):2666-2670.
44. Thompson MC, Fuller C., Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24(12):1924-1931.
45. Kool M., Koster J., Bunt J., et al. Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features. PLoS One. 2008;3(8):e3088.
46. Pfister S., Remke M., Benner A., et al. Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q, 17q, and the MYC/MYCN loci. J Clin Oncol. 2009;27(10):1627-1636.
47. Pomeroy SL, Tamayo P., Gaasenbeek M., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002;415(6870):436-442.
48. McCabe M., Ichimura K., Liu L., et al. High-resolution array-based comparative genomic hybridization of medulloblastomas and supratentorial primitive neuroectodermal tumors. J Neuropathol Exp Neurol. 2006;65(6):549-561.
49. Pfister S., Remke M., Toedt G., et al. Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. Genes Chromosomes Cancer. 2007;46(9):839-851.
50. Russo C., Pellarin M., Tingby O., et al. Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer. 1999;86(2):331-339.
51. Inda MM, Perot C., Guillaud-Bataille M., et al. Genetic heterogeneity in supratentorial and infratentorial primitive neuroectodermal tumours of the central nervous system. Histopathology. 2005;47(6):631-637.
52. Hilden JM, Meerbaum S., Burger P., et al. Central nervous system atypical teratoid/rhabdoid tumor: Results of therapy in children enrolled in a registry. J Clin Oncol. 2004;22(14):2877-2884.
53. Zhang F., Tan L., Wainwright LM, Bartolomei MS, Biegel JA No evidence for hypermethylation of the SNF5/INI1 promoter in pediatric rhabdoid tumors. Genes Chromosomes Cancer. 2002;34(4):398-405.